GLoBAL ANTIVIRAL JoURNAL - IHL Press

More documents

Recommendations

Info

page session title and author abstract 95 Co-infection with HIV and Other Viruses 97 Treatment of HBV/HIV Co-infections 88 MG Peters 97 Treatment of HCV in HIV-infected Individuals 89 Z Temesgen 98 HCV/HIV Co-infections: Challenges from the Perspective of TAG 90 T Swan 99 Tolerability of Darunavir/Ritonavir Versus Lopinavir/Ritonavir in 91 Lopinavir/Ritonavir-naïve, Treatment-experienced, Hepatitis B or C Co-infected Patients in TITAN YK Dayaram 100 The Effect of Lopinavir/Ritonavir on HIV/HCV Co-Infected Individuals 92 CA Smith 100 Pharmacokinetics of TMC125 in HIV-negative Volunteers with Mild or 93 Moderate Hepatic Impairment F Tomaka 101 Tolerability of Once-daily Darunavir/r versus Lopinavir/r in 94 Treatment-naïve, Patients Co-infected with Hepatitis B and/or C in the ARTEMIS Trial F Tomaka 102 Pharmacokinetics of Multiple-Dose Darunavir in Combination with 95 Low-Dose Ritonavir in Individuals with Impaired Hepatic Function F Tomaka 103 TMC125 Safety and Tolerability in Treatment-Experienced Hepatitis B 96 or C Co-infected Patients in DUET-1 and DUET-2 F Tomaka 105 Pharmacology and Drug Interactions of HBV and HCV Therapeutics 107 Preclinical Drug Metabolism in Viral Hepatitis Drug Discovery 97 AS Ray 107 Frontiers of Clinical Pharmacology in Hepatitis Drug Development 98 CW Flexner 109 Current and Future: HCV Maintenance Therapy 99 KL Lindsay 110 The Role of Pgp-driven Efflux on the Potency of HCV Replication Inhibitors 100 F McPhee xxiv Global Antiviral Journal Volume 3, Supplement 2
page session title and author abstract 111 Pharmacologic Evaluation of Novel Small Molecule HCV Inhibitors 101 Affecting NS5A-dependent Functions CR Wobbe 113 Optimizing the Outcome of Therapeutics for HBV and HCV 115 Measuring and Mapping Partnership Integration for Optimizing 102 Assessment and Treatment of Hepatitis C G Butt 115 Development of a Novel Mouse Model to Evaluate Single and 103 Combination Therapy Against Hepatitis B Virus MA Feitelson 116 Association of Pretreatment Serum Interferon-γ-inducible Protein 10 104 (Ip-10) Levels with Sustained Virological Response to Peginterferon Plus Ribavirin Therapy for Chronic Hepatitis C (CHC) with Virus Genotype 1 Infection M Fukuda 117 Optimizing Uptake and Response to Treatment of Hepatitis C Virus 105 (HCV) Infection in Injection Drug Users (IDUs): A Novel Model Incorporating Multidisciplinary Care, Directly Observed Therapy and Peer-support J Grebely 118 Efficacy of Pegylated Interferon Alpha-2a and Ribavirin Treatment in 106 Chronic Hepatitis C Patients Depends on Various Baseline Parameters and Early Viral Kinetics P Husa 119 Peginterferon Alpha-2a and Ribavirin Combination Therapy for Chronic 107 Hepatitis C in Patients with Hemophilia – Preliminary Report HJ Kim 120 Changes of IFN-inducible Gene (IP-10, PKR, MxA) Expressions During 108 Pegylated Interferon Alfa-2b Plus Ribavirin Therapy in HCV Genotype 1 Infected Japanese Patients R Nakao 121 Baseline Characteristics and Early Virologic Response to Telbivudine Predict 109 2‐Year Outcomes for Patients with HBeAg-negative Chronic Hepatitis B T Poynard 122 Predictors of Sustained Viral Response in the Retreatment of Previous 110 Interferon/Ribavirin Nonresponders: Results from the EPIC 3 Program T Poynard 123 Addition of Lamivudine to Patients with Chronic Hepatitis B who are 111 Viremic on Adefovir Dipivoxil Lowers Plasma HBV DNA Levels J Ryan HEP DART 2007 - Frontiers in Drug Development for Viral Hepatitis xxv
Page 1 and 2: GAJ Gl o b a l An t i v i r a l Jo
Page 3: December 9-13, 2007 • The Westin
Page 6 and 7: Support for HEP DART 2007 was provi
Page 8 and 9: Organizing Committee Eugene Schiff,
Page 11 and 12: HEP DART 2007 Frontiers in Drug Dev
Page 13 and 14: Abstract 9:00 Population Genetics o
Page 15 and 16: Abstract 9:10 The Role of Cyclophil
Page 17: Abstract 10:20 State of the Art Lec
Page 20 and 21: page session title and author abstr
Page 31 and 32: ABSTRACT 01 The Changing Global Epi
Page 33: Advances in New Models for HBV and
Page 36 and 37: Abstract 04 New Insights into the H
Page 38 and 39: Abstract 07 A Model System for Hepa
Page 40 and 41: polymorphisms/mutations. A consensu
Page 42 and 43: RESULTS: Youden indices derived fro
Page 44 and 45: Abstract 15 A Cell-Based, Miniaturi
Page 47: Diagnosis and New Treatments for HB
Page 50 and 51: HBV inoculum and monitored for 1 ye
Page 52 and 53: data indicate that host cell proces
Page 54 and 55: of at least 4 distinct non-nucleosi
Page 56 and 57: Selectivity indexes ranged from 25
Page 58 and 59: Abstract 29 Early Biochemical and V
Page 60 and 61: From the 23 patients, 20 patients (
Page 62 and 63: (Y93H) within domain 1 of NS5A is s
Page 64 and 65: Abstract 37 4-(1,1-Dioxo-1,4-dihydr
Page 67: Hepatitis B Foundation Symposium: E
Page 70 and 71: Serological tests have the ability
Page 72 and 73: In conclusion, waiting for an ideal
Page 75: Immunology & Pathogenesis HEP DART
Page 78 and 79:
mutagenesis scanning. The correlati
Page 80 and 81:
Abstract 48 Therapeutic Vaccination
Page 82 and 83:
with CD3. Serum levels of s4-1BB we
Page 85:
New Therapeutic Approaches HEP DART
Page 88 and 89:
protein Claudin-1 (CLDN1). Other fa
Page 90 and 91:
Abstract 57 HCV Infection Increases
Page 92 and 93:
Abstract 59 Bioinformatics Resource
Page 94 and 95:
Methods: Single doses of R7128 were
Page 96 and 97:
Methods: These double-blind studies
Page 98 and 99:
dilutions of ribavirin (from 20µg/
Page 100 and 101:
time not associated with bleeding o
Page 102 and 103:
and tolerability in preclinical and
Page 104 and 105:
CONCLUSIONS: Our results identify s
Page 106 and 107:
eal-time PCR for detection of LacZ
Page 109:
Resistance to Antiviral Agents HEP
Page 112 and 113:
4. Conjeevaram HS, Fried MW, Jeffer
Page 114 and 115:
ADV and subsequently became unrespo
Page 116 and 117:
showed only a 1.4-fold increase at
Page 118 and 119:
Abstract 84 Determination of Lamivu
Page 120 and 121:
deoxyguanosine analogues and lower
Page 123:
Co-infection with HIV and Other Vir
Page 126 and 127:
the primary goal of therapy. The se
Page 128 and 129:
Abstract 92 The Effect of Lopinavir
Page 130 and 131:
RESULTS: 343 and 346 patients were
Page 132 and 133:
serious hepatic AEs and hepatic AEs
Page 135 and 136:
ABSTRACT 97 Preclinical Drug Metabo
Page 137 and 138:
with the peginterferon-ribavirin co
Page 139:
CONCLUSIONS: An HCV replicon over-e
Page 143 and 144:
Abstract 102 Measuring and Mapping
Page 145 and 146:
Methods and patients: Serum IP-10 l
Page 147 and 148:
higher (P
Page 149 and 150:
Abstract 109 Baseline Characteristi
Page 151 and 152:
Abstract 111 Addition of Lamivudine
Page 153 and 154:
METHODS: Until May 2006 data of 437
Page 155:
Late Breaker Session HEP DART 2007
Page 158 and 159:
Abstract 116 Delta Hepatitis: Treat
Page 160 and 161:
RESULTS: Plasma samples were obtain
Page 162 and 163:
Author Index Author Abstract Page R
show all

GLoBAL ANTIVIRAL JoURNAL - IHL Press

Create successful ePaper yourself

Delete template?

Save as template?